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Abstract: Specific serotonin norepinephrine reuptake inhibitors (SNRIs) have been described 
as “better tolerated tricyclic antidepressants” or as “boosted” selective serotonin reuptake inhibi-
tors (SSRIs). Venlafaxine has become a therapeutic reference treatment for major depression. 
Although less widely studied, indirect comparisons with another SNRI, milnacipran, suggest an 
equivalent efficacy. This paper discusses these indirect comparisons and the recently published 
first double-blind, head-to-head comparison. Venlafaxine has potency at serotonin transporters 
which is about 30-fold greater than that at norepinephrine transporters while milnacipran has a 
similar potency at each transporter. Thus, at low doses, venlafaxine acts essentially as a SSRI, 
with significant noradrenergic activity only occurring at higher doses. To overcome the problem 
of the differing profile of venlafaxine at increasing doses, the first head-to-head study compared 
the therapeutic effects and tolerability of the two antidepressants when flexibly titrated to the 
high dose of 200 mg/day. The study showed that the two SNRIs have similar efficacy and safety 
profiles. Both drugs produced about 42% remissions at the end of the 20-week study. The most 
frequent adverse events in both groups were nausea, dizziness, headache, and sweating. Certain 
specific differences in tolerability are discussed.
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Introduction
Major depression is a common psychiatric condition with a prevalence of 5%–13% in 
the general population.1 Despite its prevalence and its consequences for both individu-
als and society in general, depression is only correctly diagnosed in 50% of cases, and 
less than 10% of patients with depression receive appropriate antidepressant treatment 
of adequate dose and duration.2 It is now generally accepted that the minimum dura-
tion of antidepressant treatment in order to prevent relapse of the current episode is 
6 months. Few randomized, double-blind, clinical studies of antidepressants, however, 
extend for this length of time.
Most antidepressants act to increase the synaptic concentration of serotonin 
(5-hydroxytryptamine, 5-HT) and/or norepinephrine (NE), generally by inhibiting 
the reuptake of one or both of these neurotransmitters. Serotonin and norepinephrine 
reuptake inhibitors (SNRIs) combine the efficacy of the tricyclic antidepressants 
(TCAs) with the tolerability of the selective serotonin reuptake inhibitors (SSRIs).3 
Milnacipran (Ixel®) and venlafaxine (Effexor®) are both SNRIs, although they differ in 
their selectivity inhibition of NE and 5-HT reuptake. Milnacipran has the most balanced 
ratio of potency for reuptake inhibition of the two neurotransmitters (5HT:NE 1:1.16).4 
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5-HT (2.22:1).5 Venlafaxine has a 30-fold greater potency 
for 5-HT.4
TCAs remain the “gold standard” for antidepressant 
efficacy, although their poor tolerability complicates their 
use at fully effective doses.6 Milnacipran has an efficacy 
comparable with that of the TCAs7 including clomipramine.8 
A post hoc analysis has shown that milnacipran has greater 
efficacy than SSRIs in more severely depressed patients.9 
A global analysis of all dual-acting antidepressants concluded 
that three antidepressants, ie, milnacipran, duloxetine, and 
mirtazapine, had “probable superior efficacy” compared 
with the SSRIs.10
Venlafaxine is a widely used antidepressant and has 
recently been described as a reference treatment for major 
depression.11 In a global analysis of all antidepressants men-
tioned above, venlafaxine was classified, along with clomip-
ramine, as having “definite superior efficacy”.10 Juxtaposition 
of studies or meta-analyses comparing   milnacipran with 
SSRIs and venlafaxine with SSRIs,3 suggests that the two 
SNRIs had similar overall efficacy. A recent meta-analysis 
of studies comparing newer dual-action antidepressants with 
SSRIs12 concluded a superior efficacy for all the dual-action 
antidepressants, including milnacipran and venlafaxine 
(as well as duloxetine, mirtazapine, mianserin, and moclo-
bemide). Again the two antidepressants showed comparable 
efficacy across all measures.
With the exception of the study described below, there 
have been no direct comparisons between milnacipran and 
venlafaxine. One difficulty of directly comparing these two 
SNRIs is the choice of dose. In the FDA labeling for Effexor 
the recommended starting dose for venlafaxine is 75 mg/day, 
which may be increased to 150 mg/day. If needed, the dose 
may be further increased up to 225 mg/day. In outpatient 
settings there is no evidence of usefulness of doses greater 
than 225 mg/day for moderately depressed patients, but more 
severely depressed inpatients responded to a mean dose 
of 350 mg/day. Certain patients, including more severely 
depressed patients, may respond better to higher doses, up 
to a maximum of 375 mg/day. Because venlafaxine has a 
30-fold selectivity for the reuptake of serotonin, at 75 mg/day 
it does not significantly modify noradrenergic neurotransmis-
sion and acts essentially as a SSRI.13 A clinically meaningful 
effect on noradrenergic neurotransmission is estimated to 
occur from about 150–200 mg/day.13 The adverse effects 
of venlafaxine have been shown to be dose-dependent.14 
Thus, depending on the dose chosen for the comparison, 
venlafaxine can be either a relatively well tolerated SSRI or 
a less well tolerated SNRI.
Milnacipran has a similar effect on both serotonin and 
norepinephrine reuptake and thus acts as an SNRI at all 
doses.3 The recommended dose of milnacipran in major 
depression is 100 mg/day, although various studies carried 
out with doses 150–300 mg/day have suggested that some 
patients may benefit from higher doses.15–17 These studies 
have shown that these higher doses of milnacipran are well 
tolerated by most patients. No new adverse effects are seen 
at higher doses.
Milnacipran and venlafaxine IR 
flexibly titrated to 200 mg/day
The first direct comparison of milnacipran and venlafaxine 
IR (immediate-release)18 was carried out at doses flexibly 
titrated up to a maximum of 200 mg/day for each compound. 
In addition, because in clinical practice a major objective is to 
achieve a long-lasting remission from depression, the study 
was carried out over a duration of 24 weeks. The choice of the 
IR formulation of venlafaxine rather than the XR (extended-
release) formulation was probably chosen to enable identical 
twice-daily dosing, although this is not mentioned in the 
publication.18
The recommended dose of milnacipran in major depres-
sion is 100 mg/day, but studies carried out at doses of 
150–300 mg/day suggest that some patients may benefit 
from higher doses18 and milnacipran is frequently used at 
these doses. The recommended dose range for venlafaxine 
in outpatients is 75–225 mg/day. Thus, the objective of 
this study was to explore the efficacy and long-term safety/ 
tolerability of milnacipran and venlafaxine administered in 
an outpatient setting at doses of up to 200 mg/day in patients 
suffering from a major depressive episode.
This multicenter, randomized, double-blind study was 
carried out in 195 adult outpatients presenting with an 
episode of recurrent, unipolar, moderate-to-severe (Mont-
gomery-Asberg Depression Rating Scale [MADRS]19 score 
$23) major depressive disorder. During the first 4 weeks 
of the study, the dose of each antidepressant was uptitrated 
(days 1–3, 25 mg/day; days 4–6, 50 mg/day; days 7–13, 
100 mg/day; days 14–28, 150 mg/day). At day 28, at the cli-
nician’s discretion, the dose was maintained at 150 mg/day, 
reduced to 100 mg/day, or increased to 200 mg/day. At the 
end of the 24-week study, the dose was downtitrated by 
50 mg/day every 5 days. The daily doses were administered 
in two identical doses morning and evening, except the initial 
dose of 25 mg/day (one morning dose only) and the dose of 
150 mg/day (50 mg morning and 100 mg evening). Depres-
sive symptoms were assessed weekly using the MADRS.Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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Of the 195 patients randomized (milnacipran 97, 
  venlafaxine 98), 134 completed 24 weeks of treatment 
(milnacipran 60, venlafaxine 74). In both groups, the main 
reason for premature withdrawal was adverse events (AEs, 
51% on milnacipran, 42% on venlafaxine). The other reasons 
for premature withdrawal, such as lack of efficacy or patient 
decision after recovery, were not stated, so it is not possible 
to analyze the dropout data in detail.
The baseline characteristics of the patients (Table 1) 
were similar in both groups, except that there were signifi-
cantly more patients with a severe depressive episode in the 
  milnacipran group (63.3% versus 54% in the venlafaxine 
group). Most patients (87%) had had previous depressive epi-
sodes which had been treated with antidepressants. The mean 
baseline MADRS score of 31.0 in the overall population 
indicated moderate to severe intensity of the depression.
At the end of the titration period, approximately 90% of 
patients were taking an antidepressant dose of either 150 or 
200 mg/day (Table 2). This percentage remained constant for 
both antidepressants through to the end of the study.
The MADRS score decreased progressively throughout 
the study and was comparable in the two treatment groups 
(Figure 1). The rate of response ($50% reduction in initial 
MADRS score) and remission (a MADRS score #10, 
  Figure 2) was not clinically or statistically different between 
the two treatment groups at week 8 or week 24. Rates of 
response and remission were also similar with both antide-
pressants in a subgroup of patients with a severe depressive 
episode (n = 104, Table 3) and in patients with a measur-
able suicide risk (“low” or “moderate” according to the 
Mini International Neuropsychiatric Interview) at baseline 
(n = 75, Table 3).
In the vast majority of cases, the therapeutic benefit 
achieved at week 8 was maintained over the long term. 
Overall, 93% of responders at week 8 were also responders at 
week 24 (milnacipran, 95%, venlafaxine 87%), while 89.3% 
of the patients in remission at week 8 were also in remission 
at week 24 (milnacipran 87%, venlafaxine 92%).
During treatment, AEs were reported by 72% patients in 
the milnacipran group and 74% patients in the venlafaxine 
group. In both groups, the most common treatment-emergent 
AEs (occurring in $10% of patients) were nausea, headache, 
dizziness, constipation, hyperhidrosis, palpitations, and dry 
mouth (Figure 3). After the end of treatment during the down-
titration, the incidence of AEs was greater in the venlafaxine 
group (14% versus 7% in the milnacipran group). In males, 
dysuria was experienced only in the   milnacipran group 
(20%), while orgasmic disorders were only reported in the 
  venlafaxine group (17%). Most of the AEs occurred during the 
first 3 weeks of treatment, and 85% of them were of mild or 
moderate severity. Five patients in the   milnacipran group and 
seven patients in the venlafaxine group experienced at least 
one serious AE. Only three serious AEs (all in the venlafaxine 
group) were considered to be possibly related to the study 
treatment (one worsening depression, one anxiety related to 
an overdose of venlafaxine, and one biliary colic).
Dysuria during treatment with milnacipran has been 
reported previously.7,20 It is probably a consequence of 
increased noradrenergic tone of the urethral sphincter.21 
This is consistent with the fact that the dysuria induced by 
milnacipran can be reversed by administration of a urinary 
tract-specific alpha1 antagonist, such as tamsulosin and 
  alfuzosin.22 Dysuria is also experienced with other antidepres-
sants having a major impact on the noradrenergic system, 
such as reboxetine.23
Orgasmic disorder was spontaneously reported in 17% 
of patients treated with venlafaxine but in no patients treated 
with milnacipran. The absence of sexual dysfunction with 
milnacipran is consistent with other studies24,25 which 
Table 1 Demographic characteristics at baseline
Milnacipran  
(n = 90)
Venlafaxine   
(n = 87)
women (%) 61.1 60.4
Mean age (years) ± SD 44.6 ± 11.4 42.7 ± 12.8
Mean duration of current episode 
(months) ± SD 
3.6 ± 2.8 3.2 ± 2.2
Patients with severe depressive  
episode (%)*
63.3 54.0
Severity of suicide risk**
  Low (%) 37.8 36.3
  Moderate (%) 4.4 4.4
  High (%) 1.1 0
MADrS (mean ± SD) 31.4 ± 4.6 30.7 ± 4.4
CGi-S (mean ± SD) 5.1 ± 0.7 5.2 ± 0.7
Notes: *Severe depressive episode as defined by DSM-IV; **Moderate or mild 
suicide risk determined using the MiNi. 
Abbreviations:  CGI-S,  clinical  global  impressions  scale;  MADRS,  Montgomery-
Asberg depression rating scale; MINI, mini international neuropsychiatric interview; 
SD, standard deviation.
Table 2 Doses of antidepressants received by patients at the end 
of the titration period
Patients (%)
Milnacipran Venlafaxine
150–200 mg/day 88.6 90.1
150 mg/day 30.4 43.8
200 mg/day 58.2 46.3
At the end of treatment, the distribution of doses did not differ significantly from 
that at the end of the titration period in the two groups.Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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have shown that milnacipran does not cause treatment-
  emergent sexual dysfunction. Antidepressant-induced sexual 
  dysfunction is generally thought to result from stimulation 
of 5-HT2 receptors,26 although this is probably not the only 
mechanism. The absence of these effects with milnacipran, 
which also stimulates serotonergic transmission but does not 
act as an antagonist at 5-HT2 receptors, suggests that sexual 
dysfunction induced via stimulation of postsynaptic 5-HT2 
receptors may be attenuated or completely blocked by simul-
taneous noradrenergic stimulation, although the mechanism 
of this effect remains to be elucidated.
The study discussed in this review shows that milnacipran 
and venlafaxine, when administered at flexible doses of up to 
200 mg/day, have similar efficacy and safety profiles. There 
are, however, certain differences between the two SNRIs that 
were not explored in this study. Whereas milnacipran has no 
effect on any cytochrome (CYP) P450 enzyme,27 venlafax-
ine is a substrate for CYP2D6 which is responsible for its 
transformation into the active metabolite, desvenlafaxine.28 
There is considerable polymorphism of CYP2D6, with nearly 
10% of “slow metabolizers” in the Caucasian population.29 
This property is likely to induce unexpected variation in 
therapeutic effect and tolerability.28 In addition, as stated in 
the FDA labeling, venlafaxine’s tolerability can be influenced 
by coadministration of drugs that inhibit CYP2D6, such as 
cimetidine and certain antipsychotics.30 A recent study has 
shown that venlafaxine intoxication frequently (in 46% of 
cases) occurs in the presence of drugs interacting at the 
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CYP P450 2DC isoenzyme, resulting in higher venlafaxine 
concentrations.31
Finally, the two antidepressants vary considerably in 
terms of safety in overdose. Milnacipran has been shown 
to be safe in overdose, with doses as high as 2.8 g causing 
no serious effects and no mortality.32 No deaths have been 
reported following milnacipran overdose, with the exception 
of a case of multiple drug overdose where high blood levels 
of milnacipran, fluoxetine, norfluoxetine, sertraline, cyame-
mazine, nordiazepam, and oxazepam were found.33 In con-
trast, lethal consequences of venlafaxine overdose have been 
reported, with a frequency of over 34 per 1000 person-years. 
This was significantly greater than other antidepressants, 
including the TCAs.34 A study   carried out in the UK showed 
that the fatal toxicity index (deaths/million prescriptions) of 
venlafaxine (13) was similar to that of TCAs such as ami-
triptyline (15).35 Another more recent fatal toxicity survey, 
however, showed greater toxicity for TCAs (13.8) than for 
venlafaxine (2.5), although the latter was considerably more 
toxic than the SSRIs (0.5).36 A prominent feature of cases of 
venlafaxine intoxication is the frequent presence (in 46% 
of cases) of drugs interacting at the CYP P450, resulting in 
higher venlafaxine concentrations.36
Conclusion
Indirect comparisons3,12 and everyday clinical experience 
has suggested that milnacipran and venlafaxine have simi-
lar efficacy. The first head-to-head comparison at a dose of 
200 mg/day18 has confirmed this suggestion. The study also 
showed that concerns about tolerability at higher doses were 
unfounded. When the SNRIs were titrated flexibly over a 
period of 4 weeks, both milnacipran and venlafaxine were 
relatively well tolerated, with about 90% of patients achieving 
doses of 150 or 200 mg/day.
Venlafaxine has become a therapeutic reference for 
major depression.11 Although less widely studied, indirect 
comparisons and the head-to-head study discussed here show 
that milnacipran can be considered to be clinically equivalent 
to venlafaxine in terms of efficacy, with certain advantages 
when sexual dysfunction, overdose, or polymedication are 
of concern.
Disclosure
The author is employed by Pierre Fabre Médicament manu-
facturers of milnacipran.
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